Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 26,636 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Healthy Volunteers
Interventions: BPN-14967, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: GERD
Interventions: Aluvra™, Saline; Device · Drug
Lead sponsor: Impleo Medical Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more

Conditions: Acute Otitis Media
Interventions: Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days; Drug
Lead sponsor: Alejandro Hoberman; Other
Eligibility: 6 Months to 23 Months
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Bardstown, Kentucky • Pittsburgh, Pennsylvania

Conditions: Adjustment Disorder With Anxious Mood
Interventions: PH94B, Placebo; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Watertown, Massachusetts • New York, New York

Conditions: Stroke
Interventions: MARK; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Everolimus, Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 34
States / cities: Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 43
States / cities: Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more

Conditions: Locally Advanced Cervical Cancer
Interventions: Volrustomig, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 15 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more

Conditions: Diabetic Foot Ulcer
Interventions: PEP (Purified Exosome Product) / TISSEEL; Biological
Lead sponsor: Rion Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Blue Ash, Ohio

Conditions: Urinary Tract Infection
Interventions: PP4001, Placebo; Drug
Lead sponsor: Pinnacle Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 25
States / cities: Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 20 more

Conditions: Wounds and Injury
Interventions: NanoDOX® Hydrogel, CO2 Ablative Fractional Laser; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1-Infection
Interventions: Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more

Conditions: Actinic Keratosis
Interventions: Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Scoliosis, Kyphosis, Kyphoscoliosis, Spinal Deformity, Spondylosis
Interventions: Not listed
Lead sponsor: Mazor Robotics; Industry
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Myocardial Infarction
Interventions: Atorvastatin calcium, Inactive Placebo; Drug
Lead sponsor: The Western Pennsylvania Hospital; Other
Eligibility: 25 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Social Anxiety Disorder (SAD)
Interventions: BVR-100, BES-100; Device
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Orlando, Florida • Boston, Massachusetts • Saint Charles, Missouri + 2 more

Conditions: Patient Readmission
Interventions: Post-discharge income supplement, Enhanced care planning; Other
Lead sponsor: AltaMed Health Services Corporation; Other
Eligibility: 55 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pediatric Cancer, Surgery
Interventions: ARISE with AR, ARISE without AR; Device
Lead sponsor: ALTality, Inc.; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Nasal Airway Obstruction
Interventions: Procedure: thermal coagulation of tissue in the nasal airway; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Ocean Springs, Mississippi

Conditions: Suicide, Suicide Attempt, Adolescent Suicidality, Suicide Ideation
Interventions: Lock and Protect is a self-administered, web-based decision aid for caregivers of adolescents at risk for suicide.; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo; Biological · Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more

Conditions: Generalized Lipodystrophy
Interventions: Mibavademab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Dallas, Texas

Conditions: Metabolic Syndrome
Interventions: Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine; Other · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes
Interventions: Ro 205-2349; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 35 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 65
States / cities: Huntsville, Alabama • Mesa, Arizona • Scottsdale, Arizona + 57 more

Search by objective public record fields.

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Novel Endoluminal Clinical TreAtment of Reflux

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

PH94B in the Treatment of Adjustment Disorder With Anxiety

EMG Controlled Device in Acute Rehabilitation After Acute Stroke

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection

Investigation of Laser Assisted Drug Delivery of NanoDOX®

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

ADDRESS - Adult Deformity Robotic vs. Freehand Surgery to Correct Spinal Deformity

To Investigate the Role of Upstream High Dose Statin in STEMI

A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Effects Of Income Supplements On 30-Day Readmissions For Vulnerable Older Adults

A Pilot Randomized Controlled Trial for Feasibility of Administering an AR Game to Postoperative Pediatric Cancer Patients

InFlux System for Nasal Breathing Improvement

Lock and Protect: Reducing Adolescent Access to Lethal Means of Suicide

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus